Penn Medicine Provider
Medical Oncology
Amy S. Clark, MD, MSCE
5.0
(338)
Accepting new patients
Sees patients age 18 and up
Rena Rowan Breast Center

About me

  • Deputy Director, Breast Cancer Clinical Trials
  • Assistant Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania

Education and training

  • Medical School: Penn State Milton S. Hershey Medical Center
  • Residency: Boston Medical Center
  • Fellowship: Hospital of the University of Pennsylvania

What my patients think about me

Average Rating
5.0

338 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

May 2025
5.0
5.0
i have stage 4 breast cancer. after meeting with dr clark i always feel secure in our game plan.
May 2025
5.0
5.0
she is a wonderful doctor and carefully thinks through all the decisions made about my care.
May 2025
5.0
5.0
dr clark is terrific. she's listens is smart and helpful. recommend in a heartbeat.
May 2025
5.0
5.0
profesional

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Clark is a Penn Medicine physician.

Qualifications and experience

My research

Clark AS, Zhao F, Klein P, Montero AJ, Falkson C, Jackson EK, Rowland K, Sardesai S, Incorvati J, Dillon P, Wolff AC, Trauger R, Heineman TC, Coffey MC, Miller KD BRACELET-01/PrE0113: A Phase II Randomized Study of Paclitaxel (Pac), Pac/Pelareorep (Pel) or Pac/Pel/Avelumab in Metastatic Hormone Receptor Positive Breast Cancer , Clinical Cancer Research : 2025


Gitto, S. B., Pantel, A. R., Maxwell, K. N., Pryma, D. A., Farwell, M. D., Liu, F., Cao, Q., O'Brien, S. R., Clark, A. S., Shah, P. D., & McDonald, E. S. FluorThanatrace PET imaging as a biomarker of response to PARP inhibitors in breast cancer , Communications medicine: 2025


Berlin, E., Ko, K., Ma, L., Messing, I., Hollawell, C., Smith, A. M., Taunk, N. K., Narayan, V., Upshaw, J. N., Clark, A. S., Shah, P. D., Knollman, H., Bhattacharya, S., Koropeckyj-Cox, D., Wang, J., Yegya-Raman, N., Han, I. S., Lefebvre, B., Li, T., Wilcox, N. S., Jung, W., Chen, J., Freedman, G. M., Ky, B. Cardiac Effects of Modern Breast Radiation Therapy in Patients Receiving Systemic Cancer Therapy , JACC. CardioOncology: 2025


Garrido-Castro AC, Kim SE, Desrosiers J, Nanda R, Carey LA, Clark AC, Sacks RL, O’Connor TP, Sinclair NF, Steve Lo KM, Thomas A, Wrabel E, O’Meara T, Lin NU, Burstein HJ, He M, Rimm DL, Mittendorf EA, Tayob N, Tolaney SM Correlation of TROP2 expression with outcomes of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer: an exploratory analysis from the phase II SACI-IO HR+ trial , San Antonio Texas Breast Cancer Symposium, San Antonio, TX : 2024


Puhalla SL, Tang G, Swain SM, Ganz PA, Lynn Henry NL, Cecchini RS, Reid SA, Rastogi P, Geyer CE, White JR, Clark AS, Haddad TC, Vidal GA, Wolmark N, Mamounas EP NRG-BR009: Phase III Trial Evaluating Addition of Adjuvant Chemotherapy to Ovarian Function Suppression + Endocrine Therapy in Premenopausal Women with pN0-1, HR+/HER2- Breast Cancer and Oncotype Recurrence Score ≤25 (OFSET) , San Antonio Breast Cancer Symposium, San Antonio, TX.: 2024


Garrido-Castro AC, Desrosiers JA, Nanda R, Abdou YG, Clark AS, Sacks RL, O'Connor TP, Sinclair NF, Lo S, Thomas A, Wrabel E, DiLullo MK, Patel A, Rahman T, O'Meara TA, Keenan T, Dillon, DA, Lin NU, Burstein HJ, Mittendorf EA, Junkins KE, Rahee HA Correlation of TROP2 expression with outcomes of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer: an exploratory analysis from the phase II SACI-IO HR+ trial , San Antonio Breast Cancer Symposium, San Antonio, TX: 2024


Linden HM, Ewen D, Mankoff D, Dehdashti F, Fowler AM, Clark AS, Specht JM, Peterson LM [18F]Fluoroestradiol (FES)-PET as a predictive measure for endocrine therapy in patients with newly diagnosed metastatic breast cancer: Results from EAI142 , San Antonio Texas Breast Cancer Symposium, San Antonio, TX: 2024


Shatsky RA, Trivedi MS, Yau C, Nanda R, Rugo HS, Davidian M, Tsiatis B, Wallace AM, Chien AJ, Stringer-Reasor E, Boughey JC, Omene C, Rozenblit M, Kalinsky KM, Elias AD, Vaklavas C, Beckwith H, Williams N, Arora M, Nangia C, Torres ETR, Thomas B, Albain KS, Clark AS, Falkson C, Hershman DL, Isaacs C, Thomas A, Tseng J, Sanford A, Yeung K, Boles S, Yi Chen Y, Huppert L, Jahan N, Parker C, Giridhar K, Howard FM, Blackwood M, Sanft T, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Symmans WF, Price E, Heditsian D, LeStage B, Perlmutter J, Pohlmann P, DeMichele A, Yee D, van ‘t Veer LJ, Hylton NM, Esserman LJ. Safety and efficacy of datopotamab-deruxtecan plus durvalumab in the I-SPY2.2 Sequential Multiple Assignment Randomized Trial , Nature Medicine: 2024


Khoury K, Meisel JL, Yau C, Rugo HS, Nanda R, Davidian M, Tsiatis B, Chien J, Wallace AM, Arora M, Rozenblit M, Hershman DL, Zimmer A, Clark AS, Beckwith H, Elias AD, Stringer-Reasor E, Boughey JC, Nangia C, Vaklavas C, Omene C, Albain KS, Kalinsky KM, Isaacs C, Tseng J, Torres ETR, Thomas B, Thomas A, Sanford A, Balassanian R, Ewing C, Yeung K, Sauder C, Sanft T, Pusztai L, Trivedi MS, Outhaythip A, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Symmans WF, Price E, Beedle C, Perlmutter J, Pohlmann P, Shatsky RA, DeMichele A, Yee D, van ‘t Veer LJ, Hylton NM, Esserman LJOuthaythip, Wen Li, Natsuko Onishi, Adam L. Asare, Philip Beineke, Peter Norwood, Lamorna Brown-Swigart, Gillian L. Hirst, Jeffrey B. Matthews, Brian Moore, W. Fraser Symmans, Elissa Price, Carolyn Beedle, Jane Perlmutter, Paula Pohlmann, Rebecca A. Shatsky, Angela DeMichele, Douglas Yee, Laura J. van ‘t Veer, Nola M. Hylton, Laura J. Esserman Datopotamab-deruxtecan in early-stage breast cancer: the phase 2 I-SPY2.2 sequential multiple assignment randomized trial , Nature Medicine: 2024


Swain S, Tang G, Puhalla SL, Ganz PA, Henry NL, Cecchini RS, Reid SA, Rastogi P, Geyer CE, White JR, Clark AS, Haddad TC, Vidal GA, Wolmark N, Mamounas EP A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+/HER2- breast cancer (BC) and oncotype recurrence score (RS) ≤25 (OFSET): NRG-BR009 , Journal of Clinical Oncology: 2024